Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients
- 15 August 2005
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- No. 36,p. 4601-4603
- https://doi.org/10.1039/b501304f
Abstract
The carboxylic acid–primary amide supramolecular heterosynthon is exploited for the generation of pharmaceutical co-crystals that contain two active pharmaceutical ingredients that are polymorphic in their pure forms.Keywords
This publication has 49 references indexed in Scilit:
- A Novel 3D Brick-Wall Coordination Network Based on Nodes with Square-Pyramidal ConnectivityAngewandte Chemie-International Edition, 2003
- Crystal engineering of the composition of pharmaceutical phasesChemical Communications, 2002
- Polymorphism inp-Hydroxybenzoic Acid: The Effect of Intermolecular Hydrogen Bonding in Controlling Proton Order versus Disorder in the Carboxylic Acid Dimer MotifAngewandte Chemie-International Edition, 2000
- Polymorphic Packing Arrangements in a Class of Engineered Organic CrystalsChemistry of Materials, 1997
- L-Proline 2,5-Dihydroxybenzoic Acid (1/1): A Zwitterion Co-crystal.Acta Chemica Scandinavica, 1995
- The structures of 2-hydroxy-5-methylbenzoic acid and dimorphs of 2,5-dihydroxybenzoic acidActa Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 1982
- The molecular packing modes and the hydrogen-bonding properties of amide:dicarboxylic acid complexesActa Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 1977
- Structure of Organic Molecular CompoundsNature, 1937
- MIXED BENZOINS. VI. FURTHER EXAMPLES OF REVERSIBILITY. THE FORMATION OF ADDITION COMPOUNDSJournal of the American Chemical Society, 1931
- XCVI.—Halogen derivatives of quinone. Part III. Derivatives of quinhydroneJournal of the Chemical Society, Transactions, 1893